These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34135112)

  • 1. A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections.
    Gege C; Bravo FJ; Uhlig N; Hagmaier T; Schmachtenberg R; Elis J; Burger-Kentischer A; Finkelmeier D; Hamprecht K; Grunwald T; Bernstein DI; Kleymann G
    Sci Transl Med; 2021 Jun; 13(598):. PubMed ID: 34135112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
    Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
    Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.
    Bernstein DI; Sawtell NM; Bravo FJ; Dixon DA; Gege C; Kleymann G
    Antiviral Res; 2023 Nov; 219():105733. PubMed ID: 37858763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
    Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
    Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
    Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents and strategies to treat herpes simplex virus infections.
    Kleymann G
    Expert Opin Investig Drugs; 2003 Feb; 12(2):165-83. PubMed ID: 12556212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiviral drugs that target herpesvirus helicase primase enzymes.
    Kleymann G
    Herpes; 2003 Aug; 10(2):46-52. PubMed ID: 14577954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.
    Gege C; Kleymann G
    Expert Opin Ther Pat; 2022 Sep; 32(9):933-937. PubMed ID: 35965439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo.
    Hou J; Zhang Z; Huang Q; Yan J; Zhang X; Yu X; Tan G; Zheng C; Xu F; He S
    BMC Infect Dis; 2017 Mar; 17(1):217. PubMed ID: 28320320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agents and strategies in development for improved management of herpes simplex virus infection and disease.
    Kleymann G
    Expert Opin Investig Drugs; 2005 Feb; 14(2):135-61. PubMed ID: 15757392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
    Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large Subunit of the Human Herpes Simplex Virus Terminase as a Promising Target in Design of Anti-Herpesvirus Agents.
    Krasnov VP; Andronova VL; Belyavsky AV; Borisevich SS; Galegov GA; Kandarakov OF; Gruzdev DA; Vozdvizhenskaya OA; Levit GL
    Molecules; 2023 Oct; 28(21):. PubMed ID: 37959793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of sulfonamide by sulfoximine within a helicase-primase inhibitor with restricted flexibility.
    Gege C; Kleymann G
    Bioorg Med Chem Lett; 2024 Jul; 106():129761. PubMed ID: 38642810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from Gilead Sciences Inc.
    Gege C; Kleymann G
    Expert Opin Ther Pat; 2024 Oct; 34(10):863-872. PubMed ID: 39262042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
    Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
    Kleymann G
    Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.
    Birkmann A; Bonsmann S; Kropeit D; Pfaff T; Rangaraju M; Sumner M; Timmler B; Zimmermann H; Buschmann H; Ruebsamen-Schaeff H
    J Med Chem; 2022 Oct; 65(20):13614-13628. PubMed ID: 36202389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targets for the development of anti-herpes compounds.
    Greco A; Diaz JJ; Thouvenot D; Morfin F
    Infect Disord Drug Targets; 2007 Mar; 7(1):11-8. PubMed ID: 17346207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.